The FDA assessed the security and usefulness of atidarsagene autotemcel according to data from 37 small children who been given atidarsagene autotemcel in two solitary-arm, open-label clinical trials As well as in an expanded entry plan.[seven] Youngsters who been given procedure with atidarsagene autotemcel ended up as compared to untreated childr